Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-07-06

FDA Approved: TAVNEOS — Supplemental Application (ChemoCentryx, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TAVNEOS (avacopan) submitted by ChemoCentryx, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAVNEOS (avacopan)

Snippet

SUPPL AP for TAVNEOS (AVACOPAN)